patient
otherwis
healthi
femal
initi
present
rightsid
weak
express
aphasia
outsid
hospit
imag
find
reveal
left
parietalthalam
lesion
suspici
highgrad
glioma
underw
subtot
resect
patholog
reveal
gbm
molecular
marker
suggest
aggress
phenotyp
ie
unmethyl
mgmt
promotor
without
isocitr
dehydrogenas
mutat
time
diagnosi
karnofski
perform
statu
entir
attribut
malign
slightli
underweight
bmi
subsequ
start
chemoradi
cours
complic
obstruct
hydrocephalu
requir
implant
intraventricular
periton
shunt
despit
standard
therapi
gbm
continu
progress
start
bevacizumab
metronom
daili
low
dose
temozolomid
secondlin
treatment
approxim
week
prior
recent
hospit
evalu
hypoxem
respiratori
failur
initi
infecti
workup
includ
blood
respiratori
cultur
well
respiratori
viral
panel
neg
improv
empir
antibiot
thought
pneumocysti
jiroveci
pneumonia
pjp
given
improv
initi
steroid
trimethoprim
sulfamethoxazol
tmpsmx
start
tmpsmx
absolut
neutrophil
count
began
drop
subsequ
readmit
malais
cough
found
absolut
neutrophil
count
notabl
absolut
lymphocyt
count
remain
persist
low
sinc
initi
chemoradi
readmit
week
prior
recent
hospit
increas
short
breath
admiss
test
posit
coronaviru
tmpsmx
chang
dapson
order
continu
prophylact
pjp
coverag
seen
outpati
oncolog
offic
visit
week
prior
admiss
time
respiratori
statu
return
baselin
karnofski
perform
statu
absolut
neutrophil
count
began
recov
howev
absolut
lymphocyt
count
remain
readmit
worsen
short
breath
confus
found
hypotens
tachycard
hypoxem
laboratori
studi
reveal
worsen
pancytopenia
elev
liver
enzym
abdomin
ultrasound
mri
demonstr
heterogen
liver
coars
echotextur
splenomegali
figur
signific
anteced
alcohol
use
liver
diseas
mri
brain
reveal
stabl
appear
gbm
start
fluid
antibiot
liver
injuri
initi
thought
drug
induc
set
bevacizumab
tmpsmx
temozolomid
dapson
routin
type
screen
note
new
warm
autoantibodi
posit
directantiglobulin
test
concern
hemolyt
anemia
although
total
indirect
direct
bilirubin
markedli
elev
could
altern
explain
liver
injuri
mgdl
respect
fibrinogen
level
also
note
low
elev
ddimer
ngml
mild
coagulopathi
pt
aptt
consist
liver
injuri
viral
studi
reveal
viru
ebv
quantit
load
intern
unit
per
ml
iuml
known
histori
ebv
infect
given
precipit
clinic
declin
liver
dysfunct
pancytopenia
hypofibrinogenemia
workup
hlh
initi
found
ferritin
level
ngml
fast
hypertriglyceridemia
mgdl
elev
solubl
receptor
unitsml
made
hlh
like
diagnosi
tabl
bone
marrow
biopsi
attempt
given
clinic
condit
stare
methylprednisolon
intraven
immunoglobulin
littl
effect
requir
multipl
transfus
blood
platelet
cryoprecipit
dissemin
intravascular
coagul
rituximab
initi
follow
daili
anakinra
notabl
respons
hematolog
paramet
requir
less
transfus
figur
unfortun
patient
condit
continu
deterior
becam
oligur
echocardiogram
reveal
takotsubopattern
cardiomyopathi
went
develop
pancreat
due
hypertriglyceridemia
given
extens
multiorgan
failur
famili
wish
initi
ventil
support
dialysi
patient
pass
away
shortli
deescal
care
patient
secondari
hlh
divers
present
make
diagnosi
difficult
obtain
frequent
use
diagnost
criterion
develop
pediatr
popul
aid
enrol
clinic
trial
commonli
use
adult
popul
usual
greater
equal
five
eight
diagnost
criteria
support
diagnosi
adult
tabl
retrospect
evalu
diagnost
perform
criteria
across
pediatr
adult
popul
debaugni
et
al
demonstr
sensit
specif
adult
five
diagnost
criteria
initi
present
notabl
author
exclud
criteria
reduc
nk
cytotox
elev
solubl
analysi
role
evalu
nkcell
activ
best
describ
pediatr
popul
usual
done
adult
patient
level
uml
cohort
patient
preval
hlh
yield
posit
predict
valu
sensit
specif
although
hemophagocytosi
hallmark
patholog
featur
hlh
patient
undergo
bone
marrow
biopsi
due
critic
ill
hemophagocytosi
neither
sensit
specif
gupta
et
al
previous
demonstr
pediatr
patient
median
time
diagnosi
hlh
initi
bone
marrow
aspir
day
suggest
diagnosi
often
made
prior
outcom
bone
marrow
biopsi
given
high
index
suspicion
hlh
patient
bone
marrow
aspir
evid
hemophagocytosi
would
alter
initi
treatment
approach
notabl
patient
receiv
standard
therapi
gbm
temozolomid
oral
alkyl
agent
commonli
associ
lymphopenia
increas
risk
opportunist
infect
due
concern
diseas
progress
patient
also
receiv
signific
dose
corticosteroid
bevacizumab
monoclon
antibodi
reduc
angiogenesi
inhibit
vegf
commonli
use
manag
gbm
also
associ
immunosuppress
infect
complic
hiv
test
neg
howev
sever
lymphopenia
count
microbiolog
evid
ebv
infect
addit
recent
treat
pjp
suspect
like
trigger
hlh
patient
reactiv
ebv
set
immunosuppress
conjunct
temozolomid
therapi
set
gbm
ebv
commonli
associ
infect
trigger
result
diagnosi
hlh
associ
poor
outcom
great
geograph
variabl
diagnosi
ebvassoci
hlh
greatest
experi
driven
asia
etoposid
dexamethason
form
mainstay
initi
treatment
includ
patient
ebvassoci
hlh
confirm
longterm
analysi
studi
administr
etoposid
patient
difficult
due
sever
hepat
dysfunct
thu
chose
initi
therapi
corticosteroid
intraven
immunoglobulin
intent
start
etoposid
within
window
rituximab
monoclon
antibodi
shown
effect
reduc
symptom
inflamm
ebv
viral
load
patient
ebvassoci
hlh
patient
continu
deterior
therapeut
decis
start
therapi
anakinra
versu
target
monoclon
antibodi
alemtuzumab
agent
use
refractori
set
manag
hlh
case
pose
sever
diagnost
therapeut
challeng
despit
make
diagnosi
toxic
profil
propos
intervent
consider
addit
patient
compet
risk
mortal
underli
malign
sever
infect
complic
multiorgan
failur
increas
use
immunosuppress
cytotox
regimen
manag
advanc
malign
like
increas
recognit
hlh
patient
solid
organ
malign
increas
awar
research
best
therapeut
approach
reduc
high
mortal
rate
addit
patient
highgrad
glioma
treat
temozolomid
monitor
sign
hlh
hlh
rare
highli
morbid
condit
adult
present
first
case
patient
develop
ebvassoci
hlh
follow
therapi
underli
gbm
addit
high
index
suspicion
diagnosi
especi
patient
solid
organ
malign
care
consid
approach
need
extrapol
therapeut
approach
evid
base
larg
deriv
pediatr
popul
